Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Trial Profile

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs PTI-125 (Primary)
  • Indications Alzheimer's disease
  • Focus First in man; Pharmacokinetics
  • Sponsors Pain Therapeutics
  • Most Recent Events

    • 14 Dec 2017 According to a Pain Therapeutics media release, full results of this study were presented at the 10th Annual International Conference on Clinical Trials on Alzheimers Disease (CTAD) 2017.
    • 24 Oct 2017 According to a Pain Therapeutics media release, this trial was supported with research grant award from the National Institute on Aging, part of the National Institutes of Health.
    • 24 Oct 2017 According to a Pain Therapeutics media release, full results of this study will be presented at the 10th Annual International Conference on Clinical Trials on Alzheimers Disease (CTAD) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top